NCT01337583撤回3 期
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 5
- 主要终点
- Efficacy as determined by HIV-1 seroconversion rate per person-years of product use, measured at the end of the investigational product use period.
研究概览
简要总结
This is a double-blind, randomized, placebo-controlled Phase III study to asses the safety and efficacy of a silicone elastomer vaginal ring containing 25mg of dapivirine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women >18 and <40 years of age who can provide informed consent
- •Available for all visits and consent to follow all procedures scheduled for the trial
- •Generally healthy and self-reported sexually active (defined as an average of at least one penetrative penile vaginal coital act per month for the last 3 months prior to enrolment)
- •HIV-negative as determined by the HIV algorithm applied at screening and enrolment
- •On a stable form of contraception and willing to continue on stable contraception for the duration of the clinical trial;
- •Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any clinically significant treatable STI, she must have initiated treatment at least 1 week prior to enrolment and have completed the full course of treatment)
- •Willing to answer questions about adherence, sexual behaviour, vaginal practices and ring acceptability;
- •Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures (e.g., by home visit or telephone; or via family or close neighbour contacts [confidentiality to be maintained])
- •Willing to refrain from participation in another research trial using drugs, vaccines, medical devices, microbicides or oral pre-exposure prophylaxis investigational drugs for the duration of the IPM 009B trial;
- •In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 35 days between menses;
- •Willing to refrain from use of vaginal products or objects including spermicides, tampons, female condoms, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches and drying agents within 14 days from enrolment and for the duration of the trial.
排除标准
- •Currently pregnant or last pregnancy within 3 months prior to screening;
- •Currently breast-feeding
- •Participated in another research trial using drugs, medical devices, microbicides or oral pre-exposure prophylaxis agents within 60 days prior to screening
- •Previously participated or currently participating in any HIV vaccine trial
- •Untreated, clinically significant urogenital infections (either symptomatic or asymptomatic), e.g., urinary tract or other sexually transmitted infections, or other gynaecological symptoms within 1 week prior to enrolment
- •History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence
- •Any gynaecological surgery within 90 days prior to enrolment
- •Any Grade 3 or 4 baseline haematology, chemistry or urinalysis laboratory value according to the DAIDS Table for Grading Adverse Experiences, or clinically significant Grade 2 findings
- •Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or a silicone elastomer
- •Any history of diabetes mellitus and chronic use of oral steroid therapy and any uncontrolled serious chronic or progressive disease
- •Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation [this includes any findings of atypical squamous cells of undetermined significance (ASCUS)]
- •Any condition(s) that, in the opinion of the investigator, might put the participant at risk, or interfere with the trial objectives, or adherence to trial requirements
研究组 & 干预措施
Dapivirine
Experimental
Vaginal ring containing 25mg of dapivirine
干预措施: Dapivirine (Drug)
Placebo Ring
Placebo Comparator
Vaginal ring containing no drug substance
干预措施: Placebo (Other)
结局指标
主要结局
Efficacy as determined by HIV-1 seroconversion rate per person-years of product use, measured at the end of the investigational product use period.
时间窗: 15 months
The primary endpoint is HIV-1 seroconversion measured by rapid and specialized laboratory tests according to a comprehensive HIV testing algorithm. This algorithm employs a series of high specificity and high sensitivity immunoassay-based HIV blood tests that minimize the chance of false positive results to determine if a subject is positive for HIV. Endpoint confirmation of HIV infection is by Western blot.
Safety as determined by grade 3 and 4 AE's, clinically significant grade 2 laboratory findings (based on DAIDS grading) and all serious AE's.
时间窗: 15 months
This will be measured by self-reports, physical examination, safety laboratory tests and other specialised investigations.
次要结局
- Adherence to the protocol-specific product regimen as determined by self-reported diary cards and questionnaires.(15 months)
- The incidence of curable STI's or pregnancy as determined by STI testing and pregnancy testing.(15 months)
研究者
研究点 (5)
Loading locations...
相似试验
撤回
3 期
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in AfricaHIV InfectionsNCT01337570International Partnership for Microbicides, Inc.
已完成
3 期
A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001Respiratory Tract DiseasesNCT00382408Duramed Research4,040
已完成
3 期
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal WomenHypoactive Sexual Desire DisorderNCT00613002BioSante Pharmaceuticals597
已完成
3 期
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional ConstipationFunctional ConstipationNCT05151328Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.648
已完成
3 期
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal WomenHypoactive Sexual Desire DisorderNCT00657501BioSante Pharmaceuticals575